


Improved Outcomes with Correction Factor



HOW IT WORKS

Control-IQ technology predicts glucose levels 30 minutes ahead and automatically adjusts insulin every five minutes.



Helps Prevent Highs

Increases basal insulin and delivers automatic correction boluses* (■) if sensor glucose is predicted to be high.

Helps Prevent Lows

Decreases or stops basal insulin if sensor glucose is predicted to be low.



SETTING UP

Control-IQ technology is the only system that allows for the customization of pump settings. Simply enter a patient's weight and average total daily insulin (TDI) use to get started.

Basal Modulation	User Modifiable	Automatic Correction Boluses
• Every Five Minutes	• Basal Rate	• Up to Once/Hour
✓ Correction Factor	✓ Correction Factor	✓ Correction Factor
• Programmed Basal Rate	• Insulin-to-Carb Ratio	• Target BG 110 mg/dL (6.1 mmol/L)

Note: The American Association of Clinical Endocrinologists(AACE)/American College of Endocrinology insulin pump management task force consensus guidelines published in 2014 can help guide initial pump settings.¹



STUDY


Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real-World Clinical Care.²

Methods

- Retrospective analysis of data from 22,000 users of Control-IQ technology for 3+ months
- Explored association of basal rates, correction factor, and insulin-to-carb ratios (standardized by TDI) with glycemic outcomes
- Linear regression to determine importance of parameters of predictors of glycemic outcomes

Results

Correction Factor Quartiles



+14%

Time in range difference between the

most aggressive (Q1) and least aggressive (Q4) correction factor quartiles, with **minimal impact on hypoglycemia**.

More aggressive 79.1% TIR

Less aggressive 65% TIR


The quartile with the most aggressive correction factor only increased 0.15% of values below 70 mg/dL (3.9 mmol/L) vs. the most conservative quartile.

Conclusion

Revisit baseline pump settings to optimize clinical outcomes with Control-IQ technology. Focusing on the correction factor can help:

- Reduce constraints on the basal algorithm
- Make user-given boluses more impactful
- Make automatic correction boluses more impactful

Average Correction Factor Settings



Majority had correction factor that was less aggressive than the AACE guidelines

■ Recommended baseline settings¹

* If glucose values are predicted to be above 180 mg/dL (10.0 mmol/L), Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL (6.1 mmol/L) and delivers 60% of that value.

References: 1. Grunberger G, Abelseth JM, Bailey TS, et al. Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. *Endocr Pract.* 2014;20:463–489. 2. Messer LH, Breton MD. Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real World Clinical Care. *Diabetes Technol Ther.* 2023;25(12):877-882. doi:10.1089/dia.2023.0308

Important Safety Information: The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices. Control-IQ technology is intended for use with a compatible continuous glucose monitor (CGM) and the t:slim X2 insulin pump to automatically increase, decrease, and suspend delivery of basal insulin based on CGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. The pump is indicated for use in persons six years of age and greater who require a total daily insulin dose of at least 10 units and who weigh at least 25 kilograms. The pump is intended for single patient use. Refer to the User Guide for a list of compatible insulins.

WARNING: Control-IQ technology should not be used by anyone under the age of 6 years old. It should also not be used in users who require less than 10 units of insulin per day or who weigh less than 25 kilograms.

The System is not indicated for use in pregnant women, people on dialysis, or critically ill users. Do not use the System if using hydroxyurea. Users of the pump and the System must: be willing and able to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

©2024 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Tandem logos, Control-IQ, and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners. ML-1014724_A